ICS/LABA Combination With Integrated Dose Counter and Smartphone APP to Improve Asthma Control
The Use of fluticasone Propionate/Salmeterol Inhaler With Integrated Dose Counter and Smartphone Self Management to Improve Airway Inflammation and Asthma Control
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei City, Taiwan, 886
- Taipei Veterans General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Symptomatic asthmatics free of controller medication for at least 3 months
- Aged from 20 to 70 years
- Life-long smoking index < 10 pack-years
Exclusion Criteria:
- COPD, clinically overt bronchiectasis, lung cancer, active tuberculosis, or other known specific pulmonary disease.
- A chest X-ray indicating diagnosis other than asthma that might interfere with the study.
- Major disease abnormalities are uncontrolled on therapy.
- Alcohol or medication abuse.
- Patients had lower respiratory tract infections or received systemic steroid in the 4 weeks prior to the commencement of study.
- Unable or unwilling to comply with all protocol
- Unable to use Smartphone
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Usual care
"Usual care" means that intervention by fluticasone/salmeterol 125/25 2 puffs bid plus salbutamol as needed acts as asthma controller and patients will be scheduled to revisit clinics.
|
fluticasone/salmeterol 125/25 ug/puff, 2 puff bid plus salmeterol as-needed
Other Names:
|
|
Experimental: Usual care+Smartphone action
Intervention by fluticasone/salmeterol 125/25 2 puffs bid plus salbutamol as needed and Smartphone action, which provides the real-time health information of surroudings and actively remind the patients to use controller.
|
fluticasone/salmeterol 125/25 ug/puff, 2 puff bid plus salmeterol as-needed
Other Names:
Smartphone applications (Apps) can provides a platform not only to share health information at the point-of-living, including health assessments, personalized health plans, but also to remind the patients' medication adherence regularly.
With the application of modern smartphone-based asthma self management deserves further investigation to improve asthma control.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes of airway inflammation profile
Time Frame: Changes of airway inflammation profile from baseline at 24 weeks
|
measurement including exhaled NO, cell counts and mediator in induced sputum before (baseline, wk0) and after treatment (wk 24)
|
Changes of airway inflammation profile from baseline at 24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
changes of scores of asthma control questionnaire
Time Frame: Changes of scores of asthma control questionnaire from baseline at 24 weeks
|
scores of questionnaire of asthma control test (ACT)
|
Changes of scores of asthma control questionnaire from baseline at 24 weeks
|
|
Changes of lung function parameters
Time Frame: Changes of lung function parameters (FEV1, FVC) from baseline at 24 weeks
|
Changes of lung function parameters (FEV1, FVC) from baseline at 24 weeks
|
|
|
Numbers of rescue medication use
Time Frame: Total numbers of rescue medication use during 24-week period
|
Total numbers of rescue medication use during 24-week period
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Kang-Cheng Su Su, Md. MS, Taipei Veterans General Hospital, Taiwan
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20140218
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.